Penumbra (PEN) Equity Income (2017 - 2018)
Penumbra's (PEN) quarterly Equity Income came in at -$920000.0 in Q3 2018, down 68.81% year-over-year from -$2.9 million in Q3 2017, and up 25.2% quarter-over-quarter from -$1.2 million in Q2 2018.
Powered by 
Analysis
Penumbra (PEN) Equity Income (2017 - 2018) Analysis & Trends
Penumbra (PEN) has reported Equity Income for 2 consecutive years, with -$920000.0 the latest figure, recorded in Q3 2018.
- On a quarterly basis, Equity Income fell 68.81% year-over-year to -$920000.0 in Q3 2018; TTM through Jun 2019 was -$920000.0, a 73.36% increase from a year earlier, with the FY2018 full-year figure at -$3.1 million, down 116.85% from the prior year.
- Equity Income was -$920000.0 for Q3 2018 at Penumbra, up from -$1.2 million in the prior quarter.
- Over five years, Equity Income peaked at -$158000.0 in Q2 2017 and troughed at -$1.2 million in Q2 2018.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.91 Bn | 178.31 Bn | 7.27 Bn | - |
| 2 | Intuitive Surgical | 124.32 Bn | 119.11 Bn | 1.96 Bn | - |
| 3 | Medtronic | 118.42 Bn | 109.60 Bn | 6.34 Bn | - |
| 4 | Stryker | 105.22 Bn | 101.74 Bn | 4.50 Bn | - |
| 5 | Boston Scientific | 66.57 Bn | 66.03 Bn | 3.85 Bn | - |
| 6 | Edwards Lifesciences | 49.76 Bn | 45.51 Bn | 1.35 Bn | - |
| 7 | Alcon | 33.91 Bn | 32.46 Bn | 1.68 Bn | - |
| 8 | Dexcom | 32.28 Bn | 30.33 Bn | 830.00 Mn | - |
| 9 | Steris | 21.10 Bn | 20.62 Bn | 684.20 Mn | - |
| 10 | Penumbra | 12.58 Bn | 11.93 Bn | 264.94 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2018 | -920,000.00 |
| Jun 30, 2018 | -1.23 Mn |
| Mar 31, 2018 | -951,000.00 |
| Dec 31, 2017 | -727,000.00 |
| Sep 30, 2017 | -545,000.00 |
| Jun 30, 2017 | -158,000.00 |